Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
CIKN/A
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.12 million
Profitability
Miscellaneous
Employees291
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.01) EPS for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.01. The company earned $10.80 million during the quarter, compared to analysts' expectations of $7.16 million. Cronos Group had a return on equity of 60.20% and a net margin of 2,521.25%. The business's quarterly revenue was up 217.6% on a year-over-year basis. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
12 Wall Street analysts have issued twelve-month price objectives for Cronos Group's shares. Their predictions range from $17.00 to $30.00. On average, they expect Cronos Group's share price to reach $22.7383 in the next year. This suggests a possible upside of 97.2% from the stock's current price. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
Media stories about CRON stock have been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cronos Group earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Cronos Group.
Are investors shorting Cronos Group?
Cronos Group saw a increase in short interest in August. As of August 31st, there was short interest totalling 38,150,000 shares, an increase of 6.2% from the July 31st total of 35,930,000 shares. Based on an average trading volume of 4,560,000 shares, the short-interest ratio is presently 8.4 days. Currently, 21.7% of the shares of the stock are sold short. View Cronos Group's Current Options Chain.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), Aurora Cannabis (ACB), STADA Arzneimittel (STDAF), Tilray (TLRY), USANA Health Sciences (USNA), Sundial Growers (SNDL), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN) and FitLife Brands (FTLF).
What other stocks do shareholders of Cronos Group own?
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.
- Mr. William Hilson, Chief Commercial Officer
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.70%), ETF Managers Group LLC (1.78%), Morgan Stanley (0.28%), Janus Henderson Group PLC (0.24%), Janus Henderson Group PLC (0.24%) and Swiss National Bank (0.21%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Toronto Dominion Bank, Toronto Dominion Bank, Connor Clark & Lunn Investment Management Ltd., CIBC Asset Management Inc, Cetera Advisor Networks LLC, Advisory Services Network LLC and SeaCrest Wealth Management LLC.
Which institutional investors are buying Cronos Group stock?
CRON stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Vanguard Group Inc., Janus Henderson Group PLC, Janus Henderson Group PLC, D. E. Shaw & Co. Inc., Bank of America Corp DE, Alberta Investment Management Corp and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $11.53.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $3.93 billion and generates $12.12 million in revenue each year. The company earns $-14,640,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Cronos Group employs 291 workers across the globe.View Additional Information About Cronos Group.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
